Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Joshua R. Barton, Adam E. Snook & Scott A. Waldman. (2021) From leptin to lasers: the past and present of mouse models of obesity. Expert Opinion on Drug Discovery 16:7, pages 777-790.
Read now
Read now
Iman O. Sherif, Alaa A. Alshaalan & Nora H. Al-Shaalan. (2020) Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury. Renal Failure 42:1, pages 208-215.
Read now
Read now
Maria del Mar Gutierrez, Mª Gracia Mateo, Noemí Corbacho, Francesc Vidal & Pere Domingo. (2019) Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism & Toxicology 15:10, pages 787-802.
Read now
Read now
André Jacques Scheen. (2018) The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety 17:4, pages 387-405.
Read now
Read now
Radhika Sharma & Shubhangi S. Soman. (2016) Design and synthesis of novel diamide derivatives of glycine as antihyperglycemic agents. Synthetic Communications 46:15, pages 1307-1317.
Read now
Read now
Simona Cernea, Avivit Cahn & Itamar Raz. (2016) Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety 15:5, pages 697-707.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Articles from other publishers (45)
Hyounggyoon Yoo, Wonsuk Shin, BackHwan Lee, JinSoo Park, Yilseob Lee & Anhye Kim. (2023) Pharmacokinetics and Food Effect Between a 100‐mg Sustained‐Release Tablet and a 50‐mg Immediate‐Release Tablet of Vildagliptin in Healthy Subjects. Clinical Pharmacology in Drug Development.
Crossref
Crossref
Jaya P. Ambhore, Purushottam R. Laddha, Anjali Nandedkar, Prashant V. Ajmire, Deshraj S. Chumbhale, Ashish B. Navghare, Vitthal G. Kuchake, Prashant J. Chaudhari & Vaibhav S. Adhao. (2023) Medicinal chemistry of non-peptidomimetic dipeptidyl peptidase IV (DPP IV) inhibitors for treatment of Type-2 diabetes mellitus: Insights on recent development. Journal of Molecular Structure 1284, pages 135249.
Crossref
Crossref
Eiji Kutoh, Alexandra N. Kuto, Midori Akiyama, Eri Ozawa & Rumi Kurihara. (2023) Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid. European Journal of Clinical Pharmacology 79:7, pages 947-959.
Crossref
Crossref
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Raffaella Buzzetti, Ernesto Maddaloni, Jason Gaglia, R. David Leslie, F. Susan Wong & Bernhard O. Boehm. (2022) Adult-onset autoimmune diabetes. Nature Reviews Disease Primers 8:1.
Crossref
Crossref
Chao Lin, Ying Kong, Furong Wang, Rong Rong, Xiangping Li, Rensong Xiao, Ziqi Wu, Qiuyan Zhang & Lin Wang. (2022) Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. Bioorganic Chemistry 123, pages 105767.
Crossref
Crossref
Lu Wang, Jinmiao Lu, Sufeng Zhou, Yuqing Zhao, Lijun Xie, Chen Zhou, Juan Chen, Sijia Ding, Daosheng Xie, Juping Ding, Qiang Yu, Hong Shen, Guangtao Hao & Feng Shao. (2021) First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clinical Drug Investigation 41:11, pages 999-1010.
Crossref
Crossref
Habib Yaribeygi, Stephen L. Atkin, Fabrizio Montecucco, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2021) Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus. BioMed Research International 2021, pages 1-7.
Crossref
Crossref
Min Wu, Qian‐Qian Li, Hong Zhang, Xiao‐Xue Zhu, Xiao‐Jiao Li, Ying Li, Hai‐Gang Sun & Yan‐Hua Ding. (2021) Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus. Clinical Pharmacology in Drug Development 10:6, pages 660-668.
Crossref
Crossref
Ahmet AKTAŞ & Zeynep OZAN. (2020) THE EFFICACY AND SAFETY OF VILDAGLIPTIN TREATMENT FOR NONALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES MELLITUS. Cumhuriyet Medical Journal.
Crossref
Crossref
Jing Huang, Yuntao Jia, Shusen Sun & Long Meng. (2020) Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacology and Toxicology 21:1.
Crossref
Crossref
Meng-meng Ning, Wen-ji Yang, Wen-bo Guan, Yi-pei Gu, Ying Feng & Ying Leng. (2020) Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2. Acta Pharmacologica Sinica 41:11, pages 1446-1456.
Crossref
Crossref
Anca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, Dragana Nikolic, Angelo Maria Patti & Ali A. Rizvi. (2020) The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism 109, pages 154295.
Crossref
Crossref
Ying Han, Liqing Chen, Wei Liu, Xin Xin, Lingwei Meng, Xiaoyang Chu, Wei Huang, Mingji Jin & Zhonggao Gao. (2019) An HPLC–MS/MS method for quantitation of trelagliptin and application in a comparative pharmacokinetic study. Bioanalysis 11:19, pages 1755-1765.
Crossref
Crossref
Mirza Muhammad Faran Ashraf Baig, Muhammad Naveed, Muhammad Abbas, Said Abasse Kassim, Muhammad Sohail, Sana Ullah, Muhammad Rizwan Younis, Waqas Nawaz, Ghulam Jilany Khan & Muhammad Tayyab Ansari. (2019) Evaluation of chitosan/eudragit hybrid coating over cubic DNA nanospheres with superior stability and therapeutic outcomes. Journal of Drug Delivery Science and Technology 52, pages 577-585.
Crossref
Crossref
Mirza Muhammad Faran Ashraf Baig, Muhammad Naveed, Muhammad Abbas, Wen Chunxia, Sana Ullah, Muhammad Hasnat, Asam Shad, Muhammad Sohail, Ghulam Jilany Khan & Muhammad Tayyab Ansari. (2019) DNA scaffold nanoparticles coated with HPMC/EC for oral delivery. International Journal of Pharmaceutics 562, pages 321-332.
Crossref
Crossref
Mirza Muhammad Faran Ashraf Baig, Muhammad Naveed, Muhammad Abbas, Said Abasse Kassim, Ghulam Jilany Khan, Sana Ullah, Muhammad Sohail, Waqas Nawaz, Muhammad Rizwan Younis & Muhammad Tayyab Ansari. (2019) Chitosan-coated rectangular DNA nanospheres for better outcomes of anti-diabetic drug. Journal of Nanoparticle Research 21:5.
Crossref
Crossref
Eiji Kutoh, Asuka Wada & Jyunka Hayashi. (2018) Regulation of Free Fatty Acid by Sitagliptin Monotherapy in DRUG-NAÏVE Subjects with Type 2 Diabetes. Endocrine Practice 24:12, pages 1063-1072.
Crossref
Crossref
Wei-Ran Gen, Chun-Yan Fu, Hui-Hui He, Ming-Zhi Zheng, Lin-Lin Wang, Yi Yang, Yue-Liang Shen & Ying-Ying Chen. (2018) Linagliptin improved myocardial function recovery in rat hearts after a prolonged hypothermic preservation. Life Sciences 210, pages 47-54.
Crossref
Crossref
María José Ojeda-Montes, Aleix Gimeno, Sarah Tomas-Hernández, Adrià Cereto-Massagué, Raúl Beltrán-Debón, Cristina Valls, Miquel Mulero, Gerard Pujadas & Santiago Garcia-Vallvé. (2018) Activity and selectivity cliffs for DPP-IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening. Medicinal Research Reviews 38:6, pages 1874-1915.
Crossref
Crossref
Chayakrit Krittanawong, Andrew Xanthopoulos, Takeshi Kitai, Natalia Branis, HongJu Zhang & Marrick Kukin. (2017) DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics. Heart Failure Reviews 23:3, pages 355-361.
Crossref
Crossref
R. Gómez-Huelgas, F. Gómez Peralta, L. Rodríguez Mañas, F. Formiga, M. Puig Domingo, J.J. Mediavilla Bravo, C. Miranda & J. Ena. (2018) Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano. Revista Española de Geriatría y Gerontología 53:2, pages 89-99.
Crossref
Crossref
R. Gómez-Huelgas, F. Gómez Peralta, L. Rodríguez Mañas, F. Formiga, M. Puig Domingo, J.J. Mediavilla Bravo, C. Miranda & J. Ena. (2018) Treatment of type 2 diabetes mellitus in elderly patients. Revista Clínica Española (English Edition) 218:2, pages 74-88.
Crossref
Crossref
R. Gómez-Huelgas, F. Gómez Peralta, L. Rodríguez Mañas, F. Formiga, M. Puig Domingo, J.J. Mediavilla Bravo, C. Miranda & J. Ena. (2018) Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano. Revista Clínica Española 218:2, pages 74-88.
Crossref
Crossref
Vladimir V. Kouznetsov & Carlos E. Puerto Galvis. (2018) Strecker reaction and α-amino nitriles: Recent advances in their chemistry, synthesis, and biological properties. Tetrahedron 74:8, pages 773-810.
Crossref
Crossref
Beverley Balkau, Bernard Charbonnel, Alfred Penfornis, Nora Chraibi, Amir Lahouegue, Céline Faure, Florence Thomas-Delecourt & Bruno Detournay. (2017) The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study. Diabetes Therapy 8:5, pages 1147-1162.
Crossref
Crossref
Stephen L. Atkin, Niki Katsiki, Maciej Banach, Dimitri P. Mikhailidis, Matteo Pirro & Amirhossein Sahebkar. (2017) Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials. Journal of Diabetes and its Complications 31:9, pages 1458-1464.
Crossref
Crossref
Christoph Reichetzeder, Karoline von Websky, Oleg Tsuprykov, Azadeh Mohagheghi Samarin, Luise Gabriele Falke, Sulistyo Emantoko Dwi Putra, Ahmed Abdallah Hasan, Viktoriia Antonenko, Caterina Curato, Jörg Rippmann, Thomas Klein & Berthold Hocher. (2017) Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury. British Journal of Pharmacology 174:14, pages 2273-2286.
Crossref
Crossref
Andrew J. Krentz & Alan J. Sinclair. 2017. Diabetes in Old Age. Diabetes in Old Age
298
322
.
Linnea Eriksson, Samuel Röhl, Robert Saxelin, Mariette Lengquist, Malin Kronqvist, Kenneth Caidahl, Claes-Göran Östenson & Anton Razuvaev. (2017) Effects of Linagliptin on Vessel Wall Healing in the Rat Model of Arterial Injury Under Normal and Diabetic Conditions. Journal of Cardiovascular Pharmacology 69:2, pages 101-109.
Crossref
Crossref
Jenna M. LeRoy & Samuel J. Stellpflug. 2017. Critical Care Toxicology. Critical Care Toxicology
1363
1386
.
E N Yakusheva, D S Titov & A A Nikiforov. (2016) INFLUENCE OF VILDAGLIPTIN AND GLIQUIDONE COMBINATION ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY AND EXPRESSION ON THE BACKGROUND OF NORM AND IN EXPERIMENTAL ALLOXAN-INDUCED DIABETES MELLITUS TYPE 2. I.P. Pavlov Russian Medical Biological Herald 24:3, pages 53-66.
Crossref
Crossref
Andrew J. Krentz. (2016) Hypertension in type 2 diabetes: impact of glucose-lowering medications. Cardiovascular Endocrinology 5:4, pages 137-143.
Crossref
Crossref
D. Athauda & T. Foltynie. (2016) Insulin resistance and Parkinson’s disease: A new target for disease modification?. Progress in Neurobiology 145-146, pages 98-120.
Crossref
Crossref
Charles E. Grimshaw, Andy Jennings, Ruhi Kamran, Hikaru Ueno, Nobuhiro Nishigaki, Takuo Kosaka, Akiyoshi Tani, Hiroki Sano, Yoshinobu Kinugawa, Emiko Koumura, Lihong Shi & Koji Takeuchi. (2016) Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLOS ONE 11:6, pages e0157509.
Crossref
Crossref
J. Kongwatcharapong, P. Dilokthornsakul, S. Nathisuwan, A. Phrommintikul & N. Chaiyakunapruk. (2016) Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials. International Journal of Cardiology 211, pages 88-95.
Crossref
Crossref
Zhengchao Xia, Hongyan Wei, Jingjing Duan, Ting Zhou, Zhen Yang & Feng Xu. (2016) Chronic unpredicted mild stress-induced depression alter saxagliptin pharmacokinetics and CYP450 activity in GK rats. PeerJ 4, pages e1611.
Crossref
Crossref
Jenna M. LeRoy & Samuel J. Stellpflug. 2016. Critical Care Toxicology. Critical Care Toxicology
1
25
.
Hyeon-Uk Jeong, Ju-Hyun Kim, Dae Lee, Hyun Shim & Hye Lee. (2015) In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations. Molecules 20:12, pages 21802-21815.
Crossref
Crossref
Alok Sharma, Geetanjali Paliwal, Nisha Upadhyay & Archana Tiwari. (2015) RETRACTED ARTICLE: Therapeutic stimulation of
GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. Journal of Diabetes & Metabolic Disorders 14:1.
Crossref
Crossref
Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Thomas Seck, Sanjay Patel, Hans-Juergen Woerle & Odd Erik Johansen. (2015) Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:12, pages 1225-1238.
Crossref
Crossref
E. Kutoh, M. Hirate & A. Wada. (2015) Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin. International Journal of Clinical Practice 69:11, pages 1296-1302.
Crossref
Crossref
Qing Li, Muxing Zhou, Li Han, Qing Cao, Xinning Wang, LeiLei Zhao, Jinpei Zhou & Huibin Zhang. (2015) Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors. Chemical Biology & Drug Design 86:4, pages 849-856.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref